---
title: "翰思艾泰生物醫藥科技(武漢)股份有限公司 (03378.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/03378.HK.md"
symbol: "03378.HK"
name: "翰思艾泰生物醫藥科技(武漢)股份有限公司"
industry: "生物技術"
---

# 翰思艾泰生物醫藥科技(武漢)股份有限公司 (03378.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.hanxbio.com](https://www.hanxbio.com) |

## Company Profile

翰思艾泰生物醫藥科技(武漢)股份有限公司是一家主要從事腫瘤免疫療法發現、開發及商業化的中國公司。該公司產品管線主要包括HX009、HX30和HX044等針對腫瘤學的臨床階段候選藥物、以及針對自身免疫和腫瘤市場的抗體偶聯藥物、雙特異性抗體及單克隆抗體等臨床前階段候選藥物。該公司核心產品HX009是一種自主研發的抗程序性死亡受體1(PD-1)和信號調節蛋白α(SIRPα)雙功能抗體融合蛋白。HX301是一種多靶點激酶抑製劑。HX044是雙功能抗細胞毒性T淋巴細胞相關抗原4(CTLA-4)抗體SIRPα融合蛋白。該公司還運營抗體技術平臺VersatiBody以及自身免疫疾病治療平臺autoRx40。...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-22T04:30:11.000Z

**Overall: D (0.77)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -14.63% |  |
| Net Profit YoY | -50.12% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 23.97 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.57B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.38M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -53.33% | E |
| Profit Margin | -5267.39% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -14.63% | E |
| Net Profit YoY | -50.12% | D |
| Total Assets YoY | -17.28% | E |
| Net Assets YoY | -34.46% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1.90% | D |
| OCF YoY | -14.63% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 56.81% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 翰思艾泰生物醫藥科技(武漢)股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-53.33%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-5267.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-14.63%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-50.12%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-17.28%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-34.46%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1.90%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-14.63%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "56.81%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.45 | 40/70 | - | - | - |
| PB | 23.97 | 54/70 | 22.08 | 21.58 | 21.06 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/03378.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/03378.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/03378.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.